155 related articles for article (PubMed ID: 26408685)
21. Lysophosphatidic acid promotes cell invasion by up-regulating the urokinase-type plasminogen activator receptor in human gastric cancer cells.
Kim MH; Park JS; Chang HJ; Baek MK; Kim HR; Shin BA; Ahn BW; Jung YD
J Cell Biochem; 2008 Jun; 104(3):1102-12. PubMed ID: 18247343
[TBL] [Abstract][Full Text] [Related]
22. Lysophosphatidic Acid Initiates Epithelial to Mesenchymal Transition and Induces β-Catenin-mediated Transcription in Epithelial Ovarian Carcinoma.
Burkhalter RJ; Westfall SD; Liu Y; Stack MS
J Biol Chem; 2015 Sep; 290(36):22143-54. PubMed ID: 26175151
[TBL] [Abstract][Full Text] [Related]
23. uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors.
Montuori N; Cosimato V; Rinaldi L; Rea VE; Alfano D; Ragno P
Thromb Haemost; 2013 Feb; 109(2):309-18. PubMed ID: 23238745
[TBL] [Abstract][Full Text] [Related]
24. Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.
Mahanivong C; Chen HM; Yee SW; Pan ZK; Dong Z; Huang S
Oncogene; 2008 Feb; 27(9):1273-80. PubMed ID: 17724468
[TBL] [Abstract][Full Text] [Related]
25. Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins.
Tang CH; Hill ML; Brumwell AN; Chapman HA; Wei Y
J Cell Sci; 2008 Nov; 121(Pt 22):3747-56. PubMed ID: 18940913
[TBL] [Abstract][Full Text] [Related]
26. Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner.
Gil OD; Lee C; Ariztia EV; Wang FQ; Smith PJ; Hope JM; Fishman DA
Gynecol Oncol; 2008 Feb; 108(2):361-9. PubMed ID: 18073130
[TBL] [Abstract][Full Text] [Related]
27. The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC).
Dutta S; Wang FQ; Wu HS; Mukherjee TJ; Fishman DA
Gynecol Oncol; 2011 Oct; 123(1):129-37. PubMed ID: 21782227
[TBL] [Abstract][Full Text] [Related]
28. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
van Dam PA; Coelho A; Rolfo C
Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
[TBL] [Abstract][Full Text] [Related]
29. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of uPAR promotes urokinase translocation into the nucleus and epithelial to mesenchymal transition in neuroblastoma.
Semina EV; Rubina KA; Shmakova AA; Rysenkova KD; Klimovich PS; Aleksanrushkina NA; Sysoeva VY; Karagyaur MN; Tkachuk VA
J Cell Physiol; 2020 Sep; 235(9):6268-6286. PubMed ID: 31990070
[TBL] [Abstract][Full Text] [Related]
31. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
32. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
Knör S; Sato S; Huber T; Morgenstern A; Bruchertseifer F; Schmitt M; Kessler H; Senekowitsch-Schmidtke R; Magdolen V; Seidl C
Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):53-64. PubMed ID: 17891393
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
34. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
Moreau M; Mourah S; Dosquet C
Int J Cancer; 2011 Mar; 128(6):1280-92. PubMed ID: 20473943
[TBL] [Abstract][Full Text] [Related]
35. RhoB regulates uPAR signalling.
Alfano D; Ragno P; Stoppelli MP; Ridley AJ
J Cell Sci; 2012 May; 125(Pt 10):2369-80. PubMed ID: 22366462
[TBL] [Abstract][Full Text] [Related]
36. Urokinase and urokinase receptor participate in regulation of neuronal migration, axon growth and branching.
Semina E; Rubina K; Sysoeva V; Rysenkova K; Klimovich P; Plekhanova O; Tkachuk V
Eur J Cell Biol; 2016 Sep; 95(9):295-310. PubMed ID: 27324124
[TBL] [Abstract][Full Text] [Related]
37. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
38. Expression and localization of urokinase-type plasminogen activator receptor in bovine cumulus-oocyte complexes.
García DC; Miceli DC; Rizo G; García EV; Valdecantos PA; Roldán-Olarte M
Zygote; 2016 Apr; 24(2):230-5. PubMed ID: 25939353
[TBL] [Abstract][Full Text] [Related]
39. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
40. ECRG2 regulates cell migration/invasion through urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway.
Cheng X; Shen Z; Yin L; Lu SH; Cui Y
J Biol Chem; 2009 Nov; 284(45):30897-906. PubMed ID: 19717562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
